Compare Bahtera Bumi Raya Tbk. (PGJO) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bahtera Bumi Raya Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Bahtera Bumi Raya Tbk. trades at Rp870 (market cap 688.42B, 601.7K 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Bahtera Bumi Raya Tbk. is far larger — about 6.6× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| PGJO | SCPI | |
|---|---|---|
Market Cap | 688.42B | 104.4B |
Volume | 601.7K | — |
Lot | 6.02K | — |
Turnover | 518.23M | — |
Average Price | 861.27 | — |
Value | 518.23M | — |
Indicative Equilibrium Price | 870 | — |
Indicative Equilibrium Volume | 58 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bahtera Bumi Raya Tbk.
PT Tourindo Guide Indonesia Tbk (the Company) was established based on Notarial Deed No. 22 dated February 20, 2017 of Argo Wahyu Jati, S.H., M.Kn., a public notary in Tangerang Selatan. The Company started its commercial operations in 2018.
Read more on PGJO →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
